AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing
AstraZeneca CEO Pascal Soriot’s decision to bet big on a checkpoint R&D strategy that relied heavily on its in-house combo of PD-L1 and CTLA-4 is starting to look like a blockbuster loser. And this week’s pushback on a subset of the data related to high tumor mutation burden will likely do very little to change the odds here.
Researchers for the pharma giant $AZN turned up at the European Society for Medical Oncology Immuno-Oncology 2018 Congress in Geneva this week with more stunningly poor data for the combination of Imfinzi and tremelimumab, which was outperformed by Imfinzi alone — though the monotherapy also failed to stand out in advanced cases of non-small cell lung cancer.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.